3-FA

# Research Output: 3-FA (3-Fluoroamphetamine)

**Generation Provenance ID:** 2bb4bccb-5a00-443c-91c3-d3bc707d007c  
**Research Date:** 2026-05-07  
**Substance:** 3-FA (3-Fluoroamphetamine; PAL-353)  
**Readiness Category:** Sparse/Emerging — literature is primarily preclinical; no published human studies specific to 3-FA

---

## Chemical Identity

**Systematic name:** 1-(3-fluorophenyl)propan-2-amine  
**Common names:** 3-FA, 3-fluoroamphetamine, m-fluoroamphetamine, PAL-353 (research designation)  
**Molecular formula:** C₉H₁₂FN  
**Molecular weight:** 153.20 g/mol  
**CAS number:** 1626-71-7 (free base); 1716-59-2 (hydrochloride salt)  
**PubChem CID:** 121501  
**InChIKey:** PIOCLGPCMNPZFT-UHFFFAOYSA-N  
**SMILES:** CC(N)CC1=CC=CC(F)=C1  
**IUPAC name:** 1-(3-fluorophenyl)propan-2-amine  

Confirmed by (Jiang et al. 2020 [Ref 3]) and UNODC Laboratory and Scientific Service [Ref 16]. PubChem lookup confirmed CID 121501 with identical formula, weight, and InChIKey.

**Stereochemistry:** 3-FA possesses a chiral center at the C-2 position of the propylamine chain. It is typically encountered as the racemic (±) mixture on the research chemical market. Weiss et al. (2017 [Ref 19]) demonstrated successful enantioseparation of 2-FA, 3-FA, and 4-FA by HPLC using sulfated β-cyclodextrin as a chiral selector, as well as by GC-MS derivatization. No published data on differential pharmacological activity of the individual enantiomers of 3-FA specifically, though by class inference (amphetamines generally) the (+)-enantiomer is expected to be more potent at releasing dopamine. This is a **FLAG FOR HUMAN REVIEW** — no substance-specific enantioselective pharmacology data exists.

**Physical properties:** No published melting point or aqueous solubility data specific to 3-FA were identified. The NIST WebBook lists the hydrochloride salt (CAS 1716-59-2). Puri et al. (2017 [Ref 10]) noted the free base has high passive transdermal permeation, suggesting lipophilicity compatible with membrane penetration.

**Discrepancies with seed data:** The brief lists SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID as empty. This research confirms all those fields: CID 121501, formula C₉H₁₂FN, MW 153.20, InChIKey PIOCLGPCMNPZFT-UHFFFAOYSA-N, SMILES CC(N)CC1=CC=CC(F)=C1.

---

## Pharmacology

### Mechanism of Action

3-FA (PAL-353) is a substrate-type releaser at all three monoamine transporters — dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) — functioning via the same reverse-transport mechanism as amphetamine. It promotes vesicular release of monoamines and drives them into the synapse via transporter reversal, rather than acting as a reuptake inhibitor. It is highly selective for dopamine and norepinephrine release over serotonin (Wee et al. 2005 [Ref 5]; Baumann et al. 2011 [Ref 4]).

### Monoamine Release Potency (In Vitro)

The following EC₅₀ values for monoamine release were characterized in HEK-293 cells expressing human transporters (Wee et al. 2005 [Ref 5]; confirmed in Baumann et al. 2011 [Ref 4]):

| Transporter | EC₅₀ (nM) ± S.D. |
|---|---|
| Norepinephrine (NET) | 16.1 ± 1.7 |
| Dopamine (DAT) | 24.2 ± 1.1 |
| Serotonin (SERT) | 1937 ± 202 |

**DA/5-HT selectivity ratio:** ~80 (highest among the tested analog series, which included PAL-313 at ratio ~0.67, PAL-314 at ~2.6, and PAL-303 at ~17.6)  
**NE/DA selectivity:** PAL-353 releases NE slightly more potently than DA (NE EC₅₀ 16.1 vs. DA EC₅₀ 24.2 nM)

This profile is strongly DA/NE-selective and resembles that of d-amphetamine, but with even lower 5-HT releasing potency. By comparison, MDMA has a DA/5-HT selectivity ratio of approximately 0.1 (highly serotonin-preferring). The result is that 3-FA produces stimulant effects closer to amphetamine/methamphetamine than to MDMA-type entactogens (Baumann et al. 2011 [Ref 4]).

### In Vivo Pharmacodynamics

In rat nucleus accumbens microdialysis (Baumann et al. 2011 [Ref 4]; two IV doses: 1 mg/kg then 3 mg/kg):
- **Dopamine:** PAL-353 produced the greatest DA elevation of the four tested analogs (m-FA, p-FA, m-methamphetamine, p-methamphetamine), approximately **5–14-fold above baseline**
- **Serotonin:** PAL-353 produced the lowest 5-HT elevation of the four tested analogs — confirming in vitro selectivity ratio in vivo
- **Ambulation:** PAL-353 evoked the strongest forward locomotion among all tested compounds — consistent with potent, relatively pure DA stimulant action
- **Stereotypy:** Not significantly different from the other analogs

In squirrel monkeys, PAL-353 increased nucleus accumbens DA and induced behavioral stimulant effects, whereas analogs with greater 5-HT activity did not (Kimmel et al. 2009 [Ref 8]).

In rats, PAL-353 markedly stimulated forward locomotion at doses of 2, 4, 8, and 16 µmol/kg i.p. but, like the other analogs, suppressed food intake (Wellman et al. 2009 [Ref 9]).

In mice and rats, Anchondo et al. (2025 [Ref 1]) showed:
- Locomotor ED₅₀ for 3-FA: comparable to methamphetamine (rank order: 2-FMA > meth > 3-FMA = 3-FA > 4-FMA)
- Peak locomotor count: 5905–7758 (similar to methamphetamine's peak response)
- Drug discrimination: 3-FA fully substituted for methamphetamine with ED₅₀ = 0.32–0.71 mg/kg

### TAAR1 Activity

3-FA is expected to be a TAAR1 agonist by class inference. Amphetamine-related compounds activate trace amine-associated receptor 1 (TAAR1), with activity enhanced by co-expression of monoamine transporters (DAT, NET, SERT) (Xie et al. 2007 [Ref 24]). TAAR1 activation is thought to modulate and partially regulate the stimulant effects of amphetamine-type compounds (Revel et al. 2012 [Ref 23]). **No substance-specific TAAR1 data for 3-FA is published — this is class-level inference. FLAG FOR HUMAN REVIEW.**

### Receptor Binding

No published Ki values at dopamine receptors (D₁, D₂), adrenergic receptors, or serotonin receptors (5-HT₂A, 5-HT₂B) were found specific to 3-FA. By class inference from the para-halogenated amphetamine profile (Rickli et al. 2015 [Ref 13]), fluoroamphetamines may have some affinity at 5-HT₂A receptors, but this has not been confirmed for 3-FA specifically.

### Pharmacokinetics (Animal Data Only — No Human PK Studies)

**Rat (IV bolus, 5 mg/kg)** — Jiang et al. 2020 [Ref 3]:
- C₀: 1412.09 ± 196.12 ng/mL
- Plasma half-life: **2.27 ± 0.67 h** (intravenous route in male Sprague-Dawley rats)
- Rapid clearance after transdermal patch removal

**Transdermal delivery** — Jiang et al. 2020 [Ref 3]; Puri et al. 2017 [Ref 10]:
- 10% w/w transdermal gel produced sustained delivery with short lag time
- ~70% drug permeated in vitro through human epidermis
- Iontophoresis enhanced permeation 548-fold vs. passive from PBS
- No skin irritation predicted at therapeutically relevant concentrations (EPIDERM model)

**Important gap:** No human pharmacokinetic data exist for 3-FA by any route of administration. The brief's tolerance section lists a half-life of "5 days" — this appears to be a tolerance half-life (rate of tolerance resolution), NOT a plasma elimination half-life. The plasma elimination half-life in rats is 2.27 h (IV). The clinical half-life in humans is unknown. **FLAG FOR HUMAN REVIEW: verify the tolerance half-life framing vs. plasma half-life.**

**Metabolism:** No published data on 3-FA metabolism in any species. By class analogy, fluoroamphetamines undergo beta-hydroxylation (yielding fluorophenylpropanolamines) and ring hydroxylation followed by glucuronide conjugation — as demonstrated for 4-fluoroamphetamine in humans (Toennes et al. 2020 [Ref 20]). Defluorination has been considered but is not a major pathway based on evidence from PET radiotracer work with fluorinated amphetamines (Shiue et al. 1993 [Ref 8298577]). CYP enzyme involvement has not been studied for 3-FA. By amphetamine class inference, CYP2D6 and MAO-A/MAO-B are expected to be involved. **FLAG: metabolism pathway is class-inferred, not substance-specific.**

---

## History

### Research Origins (PAL Compound Series)

3-FA was synthesized as part of the PAL (Phenylethylamine/Amphetamine Library) compound series developed at the National Institute on Drug Abuse (NIDA) Intramural Research Program, primarily by researchers Richard B. Rothman, Bruce E. Blough, and Michael H. Baumann. The PAL designation (PAL-353) identifies it as the 353rd compound in this series. The series was designed to systematically vary the position and nature of ring substituents to modulate monoamine releasing selectivity, with the goal of identifying drug candidates for cocaine use disorder treatment.

The earliest published pharmacological characterization of PAL-353 by name appears in Wee et al. (2005 [Ref 5]), which established its in vitro releasing potency profile (DA/NE/5-HT EC₅₀ values) and in vivo self-administration in rhesus monkeys. Subsequent papers (Negus et al. 2007 [Ref 6]; Wellman et al. 2009 [Ref 9]; Kimmel et al. 2009 [Ref 8]; Baumann et al. 2011 [Ref 4]; Banks et al. 2011 [Ref 7]) further characterized its behavioral and neurochemical pharmacology.

The compound was never advanced to human clinical trials despite its attractive preclinical profile. The CAS number 1626-71-7 exists in registry databases, indicating prior synthetic literature references; the exact first synthesis date is not documented in published literature accessible through this search.

### Research Chemical Market

3-FA emerged on European research chemical markets around **January 2009**, when it was first notified to the European Early Warning System by Belgian authorities [Ref 17]. This was after 4-fluoroamphetamine (4-FA) had already established a foothold in the Netherlands and other European markets.

3-FA is typically sold as a white crystalline powder (as the hydrochloride salt). Its synthesis by reductive amination of 3-fluorophenylacetone with ammonia, followed by reduction with NaBH₃CN or NaBH(OAc)₃, has been discussed in lay literature but not published in peer-reviewed journals.

The compound has appeared in drug seizure databases (EMCDDA early warning system) and analytical standards are commercially available (Caymen Chemical, Bertin Bioreagent). The UNODC Laboratory and Scientific Service maintains a record [Ref 16].

### Proposed Therapeutic Research

PAL-353 was specifically investigated as a candidate agonist pharmacotherapy for cocaine use disorder (CUD), based on its ability to:
- Reduce cocaine self-administration in non-human primates (Negus et al. 2007 [Ref 6]; Banks et al. 2011 [Ref 7]; Banks et al. 2013 [Ref 15])
- Substitute for cocaine in drug discrimination assays (Negus et al. 2007 [Ref 6])
- Have a favorable pharmacokinetic profile for transdermal delivery (Jiang et al. 2020 [Ref 3]; Puri et al. 2017 [Ref 10])

No clinical trials were initiated or registered with ClinicalTrials.gov as of the research date (May 2026). The transdermal delivery research (Puri 2017 [Ref 10]; Jiang 2020 [Ref 2, 3]) represents the most recent preclinical work toward clinical development.

---

## Subjective Effects

**Critical note:** No published controlled human studies on the subjective effects of 3-FA exist. All effect descriptions are sourced from user reports (research chemical community) and animal behavioral studies. No clinical trial data available.

### Animal Behavioral Data

- **Locomotor stimulation:** Produces methamphetamine-like peak locomotor activity in mice (5905–7758 counts, similar to methamphetamine) (Anchondo et al. 2025 [Ref 1])
- **Discriminative stimulus:** Fully substitutes for methamphetamine in drug discrimination at comparable potency (ED₅₀ 0.32–0.71 mg/kg) (Anchondo et al. 2025 [Ref 1])
- **Discriminative stimulus for cocaine:** Fully substitutes for cocaine in rhesus monkeys; substitution associated with DA/NE selectivity (Negus et al. 2007 [Ref 6])
- **Appetite suppression:** Suppresses food intake in rats similarly to amphetamine (Wellman et al. 2009 [Ref 9])
- **Reinforcement:** Self-administered by rhesus monkeys on FR-25 and progressive ratio schedules; maintains positive reinforcement comparable to related analogs (Wee et al. 2005 [Ref 5])

### Inferred Human Effects (from 4-FA survey data, class inference)

The closest published user-report survey data is for 4-FA, not 3-FA. Linsen et al. (2015 [Ref 22]) found that 4-FA's subjective effects were rated between amphetamine and MDMA — mild euphoria, stimulation, sociability, modest empathy enhancement, duration of 8–10 hours for 4-FA. Because 3-FA has a much lower 5-HT releasing potency than 4-FA (3-FA 5-HT EC₅₀ = 1937 nM vs. 4-FA ~53 nM as per Rickli et al. 2015 [Ref 13]), 3-FA's effects are expected to be more purely stimulant with less of the MDMA-like entactogenic component.

### Duration Data

The brief's duration data (total 4–6 hours oral) is sourced from community consensus (PsychonautWiki). Given the rat IV half-life of ~2.27 h, a 4–6 hour total oral duration is plausible — but no pharmacokinetic basis exists to confirm oral half-life or duration in humans. The 4-FA human PK study (Toennes et al. 2019 [Ref 21]) found peak serum concentrations at approximately 1–2 h post-oral ingestion. By analogy, 3-FA oral onset of 20–60 minutes is plausible. **FLAG FOR HUMAN REVIEW: duration data is community consensus, not verified by published human studies.**

---

## Safety & Toxicity

### Acute Toxicity

**No published LD₅₀ data for 3-FA.** No human case reports, overdose reports, or postmortem cases specific to 3-FA were identified in the published literature.

The 2025 Anchondo et al. paper [Ref 1] noted in its background: "their use produces significant adverse effects, including heart failure, cerebral hemorrhage, and death" — attributing these to fluorinated amphetamine analogs generally. These adverse event types have been documented for 4-FA (Gerostamoulos et al. 2023 [Ref 14]) and other fluoroamphetamines but not confirmed in 3-FA-specific case reports.

### Cardiovascular Risks

By mechanism (DA/NE releaser), 3-FA is expected to produce:
- Tachycardia and hypertension (via peripheral sympathomimetic action of NE release)
- Increased cardiac workload
- Potential for arrhythmia at high doses (class inference; Greene et al. 2008 [Ref 26])

No fluoroamphetamine-specific cardiotoxicity data beyond 4-FA combination cases (Gerostamoulos et al. 2023 [Ref 14]) exist.

### Stimulant Toxidrome / Overdose

Acute stimulant toxicity from amphetamine-type agents produces a sympathomimetic toxidrome: hyperthermia, tachycardia, hypertension, agitation, diaphoresis, mydriasis, and risk of seizures (Greene et al. 2008 [Ref 26]). Management involves:
- **Benzodiazepines** as first-line for agitation and seizure threshold protection
- **Active cooling** for hyperthermia (a major mortality predictor)
- **Beta-blockers are contraindicated** (risk of unopposed alpha-vasoconstriction)
- Antipsychotics carry seizure risk and QT prolongation risk (Connors et al. 2019 [Ref 25])

### Psychological Risks

By DA-selective mechanism:
- Psychosis risk (extended high-dose use; amphetamine-induced psychosis is a well-established syndrome with classic amphetamine — class inference for 3-FA)
- Paranoia, anxiety at high doses
- Compulsive redosing due to dopaminergic reward mechanism

### Neurotoxicity

Methamphetamine produces dopaminergic neurotoxicity via oxidative stress mechanisms. Whether 3-FA shares this liability is unknown — **no published neurotoxicity data for 3-FA exist.** FLAG FOR HUMAN REVIEW.

---

## Harm Reduction

### General Stimulant Harm Reduction (Class-Based)

No 3-FA-specific harm reduction literature exists. The following applies by class inference from amphetamine pharmacology:

- **Hydration:** Stimulants increase body temperature and sweating; maintain adequate fluid intake (avoid overhydration, which has been fatal in MDMA users; risk is lower with less serotonergic agents)
- **Temperature management:** Avoid hot, crowded environments; hyperthermia is a major risk factor
- **Cardiovascular monitoring:** Pre-existing cardiac conditions, hypertension, or structural heart disease are absolute contraindications
- **Dosing interval:** Redosing dramatically increases cardiovascular strain and psychological risk
- **Sleep:** Do not use before periods requiring sleep; stimulant-induced insomnia may trigger vulnerability
- **Avoid concurrent stimulants:** Combining with cocaine, other amphetamines, or caffeine multiplicatively increases cardiovascular strain
- **MAOI interaction:** DANGEROUS — combining any amphetamine-type stimulant with monoamine oxidase inhibitors causes potentially fatal hypertensive crisis and serotonin syndrome

### Testing

3-FA may not be detected by standard amphetamine immunoassay screens (designed for d-amphetamine epitopes). LC-MS/MS methods exist for identification. Reagent color tests will likely produce amphetamine-class results but cannot distinguish positional isomers. Analytical confirmation by LC-MS or GC-MS is required for positive identification (Weiss et al. 2017 [Ref 19]; forensic NPS literature).

---

## Tolerance & Dependence

### Tolerance

The brief states tolerance builds with prolonged/repeated use, with a tolerance half-life of 5 days and full reset at 5.5 days. **This appears to be an estimate derived from class analogy (amphetamine), not published 3-FA-specific data.** No published tolerance studies for 3-FA exist. FLAG FOR HUMAN REVIEW.

By mechanism, repeated DA/NE releaser use leads to dopaminergic receptor downregulation and DAT/NET upregulation, requiring dose escalation for equivalent effect — consistent with the general amphetamine tolerance mechanism.

### Cross-Tolerance

Cross-tolerance with other dopaminergic stimulants (amphetamine, cocaine, methamphetamine) is expected by mechanism. The brief lists cross-tolerances with dopamine and stimulant categories; no substance-specific cross-tolerance data exists.

### Dependence Liability

**In rhesus monkeys, PAL-353 is a positive reinforcer** under fixed-ratio and progressive-ratio schedules (Wee et al. 2005 [Ref 5]). It maintained responding similar to other DA-selective amphetamine analogs. This confirms addiction liability.

The compound's high DA/NE selectivity with minimal 5-HT activity means it lacks the self-limiting serotonergic component of MDMA (elevated 5-HT reduces reinforcing efficacy — Wee et al. 2005 [Ref 5]). This makes 3-FA more like methamphetamine in its reinforcement profile than like MDMA.

Anchondo et al. (2025 [Ref 1]) concluded its abuse potential is "comparable to that of methamphetamine."

The brief lists physical dependence as moderate and psychological dependence as moderate with high abuse potential — consistent with the preclinical self-administration data, but not from published clinical assessments. FLAG FOR HUMAN REVIEW.

---

## Interactions

**Critical note:** No published drug interaction studies exist for 3-FA specifically. All interaction data below is based on mechanism (DA/NE releasing agent), class inference from amphetamine, and general pharmacodynamic principles.

### MAOI (Monoamine Oxidase Inhibitors)
**DANGEROUS/POTENTIALLY LETHAL.** MAO inhibitors block intraneuronal metabolism of dopamine, norepinephrine, and serotonin. Combination with any amphetamine-type releaser causes massive accumulation of monoamines in the synapse, producing hypertensive crisis, hyperthermia, and serotonin syndrome. The 1965 Sjöqvist review [Ref 4952963] established the mechanism: MAO inhibition potentiates indirectly acting sympathomimetic amines. This applies to irreversible MAOIs (phenelzine, tranylcypromine) and reversible MAO-A inhibitors (moclobemide). Selegiline at higher doses also carries this risk. The brief lists tramadol as lethal — serotonin syndrome is the likely mechanism (tramadol has serotonergic activity via weak SERT inhibition, and this combined with any releaser could precipitate serotonin syndrome). **FLAG: tramadol is listed as "lethal" in seed data; this is mechanistically plausible but not confirmed by published 3-FA-specific data.**

### Tramadol
Listed as lethal in seed data. Mechanistic explanation: tramadol inhibits serotonin reuptake; combined with a monoamine releaser that even minimally releases serotonin (3-FA 5-HT EC₅₀ = 1937 nM is low but not zero), serotonin syndrome risk exists. Tramadol also lowers seizure threshold. The interaction severity listed as "lethal" is plausible for combined serotonin syndrome + seizure risk but is **not documented in published 3-FA case reports.**

### PCP (Phencyclidine)
Listed as "dangerous" in seed data. PCP is an NMDA receptor antagonist with additional monoaminergic effects; combining with a catecholamine releaser risks hyperthermia, cardiovascular instability, and psychosis. **Not documented in 3-FA-specific literature.**

### Alcohol
Listed as "unknown" in seed data. Alcohol is a CNS depressant that may mask stimulant intoxication signs while not reducing cardiovascular risk. Interactions with amphetamine-type stimulants are generally documented as cardiovascular concern (heart rate) and dehydration risk.

### Cannabis
Listed as "unknown" in seed data. Combining stimulants with cannabis may intensify anxiety and tachycardia; interaction severity varies by dose and individual.

### Cocaine
Listed as "unknown" in seed data. Combining two catecholamine releasers would multiplicatively increase cardiovascular risk (additive/synergistic tachycardia, hypertension, vasoconstriction). Potentially dangerous by mechanism.

### Caffeine
Listed as "unknown" in seed data. Mild additional cardiovascular stimulation; generally low-risk at typical caffeine doses.

---

## Legal Status

**United Kingdom:** Controlled as a **Class A drug** under the Misuse of Drugs Act 1971, covered by the amphetamine analogue clause [Ref 17].

**Germany:** Controlled under the **NpSG (Neue-psychoaktive-Stoffe-Gesetz / New Psychoactive Substances Act)** as of **November 26, 2016** [Ref 17]. Production and import for market placement, administration to another person, and trade are punishable. Possession is illegal but not separately penalized under NpSG.

**United States:** No permanent scheduling or DEA emergency scheduling specifically for 3-FA has been enacted as of the research date (May 2026). (Note: 4-fluoroamphetamine was proposed for Schedule I placement in January 2026 per Federal Register, but this ruling did not extend to 3-FA.) 3-FA **may** be considered a Schedule II controlled substance analogue under the **Federal Analogue Act** (21 U.S.C. § 813) given its structural and pharmacological similarity to amphetamine. Enforcement would be case-dependent. **FLAG FOR HUMAN REVIEW: US legal status is ambiguous — analogue act applicability is not a certainty and depends on prosecutorial interpretation.**

**Canada:** Amphetamine and its analogues are controlled under **Schedule III** of the Controlled Drugs and Substances Act (CDSA). 3-FA, as an amphetamine analogue, would likely fall under this provision, though no specific status decision for 3-FA was confirmed in publicly accessible records [web search, May 2026].

**Australia:** No specific information on explicit TGA Poisons Standard scheduling of 3-FA was identified. Amphetamine is listed in the Australian Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP); analogues may fall under this provision depending on regulatory interpretation. **New Zealand:** Classified as a Schedule 3 controlled substance (amphetamine analogue). **FLAG FOR HUMAN REVIEW: Australian legal status requires verification against current TGA Poisons Standard.**

**International:** No ECDD (Expert Committee on Drug Dependence) assessment or CND (Commission on Narcotic Drugs) action has placed 3-FA under international control as of May 2026. Not listed on any UN Convention schedule.

---

## Clinical Trials

**No registered clinical trials were found on ClinicalTrials.gov for 3-FA or PAL-353.**

3-FA was investigated as a preclinical candidate for cocaine use disorder treatment, but despite favorable preclinical data (Jiang et al. 2020 [Ref 3]; Puri et al. 2017 [Ref 10]; Negus et al. 2007 [Ref 6]) and active transdermal delivery research, no Phase I dose-escalation or human safety studies have been registered or published.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical Safety-Critical Flags

1. **FLAG: No human pharmacokinetic data.** The rat IV half-life is 2.27 h, but oral human half-life is unknown. The tolerance half-life listed as "5 days" in seed data appears to be class-derived and is not from any published source — requires editorial verification of what this value represents.

2. **FLAG: Dose range not verified by published human studies.** The dose data (threshold 10 mg, common 30–50 mg, heavy 70+ mg oral) is sourced exclusively from community consensus (PsychonautWiki). No controlled human dosing studies exist. These values are broadly plausible given the pharmacological profile but should be labeled as community-consensus data.

3. **FLAG: Interaction severities not confirmed by published 3-FA-specific data.** Tramadol (lethal) and PCP (dangerous) interaction severities in seed data are mechanistically plausible but unconfirmed in published 3-FA case reports. They rest entirely on class-level mechanism reasoning.

4. **FLAG: US legal status is ambiguous.** 3-FA is not explicitly scheduled; Federal Analogue Act applicability is case-dependent.

5. **FLAG: Australian legal status not confirmed.** No explicit TGA scheduling documentation for 3-FA was found.

6. **FLAG: No published human adverse event or overdose data.** All safety data is class inference. Any section describing toxic dose or overdose presentation should be explicitly labeled as class inference.

### Data Gaps

7. **No published LD₅₀ data** for 3-FA in any species. Exact toxic dosage unknown.

8. **No substance-specific TAAR1 data.** Class-level inference only.

9. **No published receptor binding data** (Ki at DA, 5-HT, adrenergic receptors) for 3-FA specifically.

10. **No published neurotoxicity data** for 3-FA. Methamphetamine-like neurotoxicity is possible but uncharacterized.

11. **No human pharmacokinetic data** (bioavailability, Tmax, Cmax, clinical half-life, metabolism) for any route.

12. **No stereoisomer pharmacology data** — which enantiomer is more potent at DAT/NET/SERT is unknown.

13. **No metabolic pathway data** for 3-FA specifically. 4-FA comparator (beta-hydroxylation, ring hydroxylation via glucuronidation) used as class inference.

14. **No clinical trials registered or published.** Despite preclinical cocaine use disorder research, clinical development has not been initiated.

15. **Discovery/first synthesis date** not confirmed from published academic literature. PAL compound series is from NIDA; exact first synthesis date is not documented in accessible records.

16. **Duration data** (4–6 h total oral) is community consensus only; not verified against human pharmacokinetic studies.

### Contradictions with Seed Data

- **Seed data half-life listed as "5 days":** This appears to represent tolerance half-life (rate of tolerance resolution), not plasma elimination half-life. The published rat IV plasma half-life is 2.27 h. These are completely different parameters. The generation agent must distinguish these clearly.

- **SMILES, formula, MW, InChIKey, PubChem CID** were empty in seed data — all confirmed by this research.